Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
22.65
+0.31 (1.39%)
Apr 13, 2026, 9:54 AM EDT - Market open
Arcus Biosciences Revenue
In the year 2025, Arcus Biosciences had annual revenue of $247.00M, down -4.26%. Arcus Biosciences had revenue of $33.00M in the quarter ending December 31, 2025, with 26.92% growth.
Revenue (ttm)
$247.00M
Revenue Growth
-4.26%
P/S Ratio
11.34
Revenue / Employee
$410,982
Employees
601
Market Cap
2.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.00M | -11.00M | -4.26% |
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
| Dec 31, 2019 | 15.00M | 6.65M | 79.58% |
| Dec 31, 2018 | 8.35M | 6.94M | 491.15% |
| Dec 31, 2017 | 1.41M | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Travere Therapeutics | 490.73M |
| Arcutis Biotherapeutics | 376.07M |
| IDEAYA Biosciences | 218.71M |
| Soleno Therapeutics | 190.41M |
| Beam Therapeutics | 139.74M |
| Tango Therapeutics | 62.38M |
| Alumis | 24.05M |
| Relay Therapeutics | 15.36M |
RCUS News
- 3 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 6 weeks ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 6 weeks ago - Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer - Business Wire
- 2 months ago - Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates - Business Wire
- 3 months ago - Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs - Business Wire
- 4 months ago - Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug - Benzinga